In gynecologic oncology, ICIs targeting programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have advanced from second-line to first-line treatment for advanced/recurrent cervical and endometrial carcinomas. The gene discussed is CTLA4; the disease is endometrial carcinoma.